SHR-A1811 + adebelimab + bevacizumab + SHR-8068

SHR-A1811 + adebelimab + bevacizumab + SHR-8068 is an experimental combination regimen composed of four agents: - **SHR-A1811** is an antibody-drug conjugate (ADC) targeting HER2 (ErbB-2) with a topoisomerase I inhibitor payload, under development for advanced HER2-positive and HER2-mutant solid tumors[1][3][5]. - **Adebelimab** is an anti-PD-1 monoclonal antibody immune checkpoint inhibitor in clinical development for various cancers. - **Bevacizumab** is a humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), used to inhibit angiogenesis for malignant solid tumors and approved for several indications including colorectal, lung, breast, renal, and ovarian cancers[2][4][6][8]. - **SHR-8068** is an experimental small molecule immune checkpoint inhibitor (TIGIT inhibitor) in clinical development for solid tumors. This combination is under clinical investigation as part of modern immunotherapy-based regimens for advanced solid tumors, especially those with HER2 alterations, aiming to provide synergistic anti-tumor activity by combining antibody-drug conjugate cytotoxicity, dual immune checkpoint inhibition, and anti-angiogenesis.

Brand names

Avastin